GABAPENTIN CAPSULES

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Bahan aktif:

GABAPENTIN

Boleh didapati daripada:

RANBAXY PHARMACEUTICALS CANADA INC.

Kod ATC:

N02BF01

INN (Nama Antarabangsa):

GABAPENTIN

Dos:

100MG

Borang farmaseutikal:

CAPSULE

Komposisi:

GABAPENTIN 100MG

Laluan pentadbiran:

ORAL

Unit dalam pakej:

30/100/500

Jenis preskripsi:

Prescription

Kawasan terapeutik:

MISCELLANEOUS ANTICONVULSANTS

Ringkasan produk:

Active ingredient group (AIG) number: 0125929001; AHFS:

Status kebenaran:

CANCELLED PRE MARKET

Tarikh kebenaran:

2023-07-24

Ciri produk

_ _
_ _
_Page 1 of 28_
PRODUCT MONOGRAPH
PR
GABAPENTIN CAPSULES
Gabapentin Capsules USP
100 mg, 300 mg, and 400 mg
Antiepileptic Agent
Ranbaxy Pharmaceuticals Canada Inc., Date of Preparation: August 20,
2009.
2680 Matheson Blvd. E., Suite 200
Mississauga, Ontario
L4W 0A5
Submission Control No: 132106
_ _
_ _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..............................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
....…...........................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................3
ADVERSE
REACTIONS....................................................................................................5
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND
ADMINISTRATION..............................................................................13
OVERDOSAGE
................................................................................................................15
ACTION AND CLINICAL PHARMACOLOGY
............................................................15
STORAGE AND
STABILITY..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
....................................................................20
PHARMACEUTICAL
INFORMATION..........................................................................20
CLINICAL
TRIALS..........................................................................................................21
DETAILED
PHARMACOLOGY..............................................................